Femara is a prescription medication that contains the active ingredient letrozole. It is marketed as a pill and is available in a 2.5 mg strength. In Hong Kong, Femara is regulated by the Department of Health and is prescribed for women’s health, specifically as part of oncology support for hormone-dependent breast cancer. The drug is produced by Novartis and is classified under the therapeutic category of women’s health and oncology support.
Letrozole belongs to a class of drugs known as aromatase inhibitors. Aromatase is an enzyme that converts androgens (such as testosterone) into estrogens. By blocking this enzyme, letrozole markedly reduces the production of estrogen in the body. Lower estrogen levels help to slow the growth of estrogen-receptor-positive (ER+) breast cancer cells, which rely on estrogen to proliferate. The medication is taken orally, is rapidly absorbed, and reaches peak plasma concentrations within a few hours. Its biological activity persists throughout the dosing interval, supporting once-daily administration.
Femara is prescribed only for postmenopausal women because aromatase inhibition has minimal effect on estrogen production in premenopausal ovaries.
While Femara’s primary indication is breast cancer, clinicians sometimes prescribe letrozole for ovulation induction in women with polycystic ovary syndrome (PCOS) who have not responded to first-line fertility treatments. This use is off-label, meaning it is not approved by regulatory agencies in Hong Kong. Off-label use requires careful medical supervision, individualized risk assessment, and monitoring of ovarian response.
Disclaimer: Off-label use of Femara should only be undertaken under the guidance of a qualified healthcare provider.
These effects are usually mild to moderate and often improve with continued therapy or supportive measures.
If any of these serious symptoms occur, patients should seek immediate medical attention.
Patients should provide a complete medication list-including over-the-counter drugs, supplements, and herbal products-to their healthcare provider before starting Femara.
Special populations: For ovulation induction (off-label), dosing schedules may differ (e.g., intermittent dosing during specific days of the menstrual cycle). This regimen should only be prescribed by a fertility specialist.
Patients should maintain regular appointments with their oncology team to review test results and adjust therapy as needed.
This article provides educational information about Femara and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Femara is not indicated for weight management. Its primary action is to reduce estrogen production, and any effect on body weight is incidental and not supported by clinical evidence.
Report the symptom to your healthcare provider promptly. They may recommend analgesics, physiotherapy, or assess bone health before continuing therapy.
Femara can alter lipid profiles, but concurrent use with statins is generally considered safe. Your doctor should monitor cholesterol levels regularly.
Estrogen suppression begins within days of the first dose, with near-maximal reduction typically achieved after two weeks of continuous therapy.
Yes, but keep the medication in its original packaging with the prescription label. Carry a copy of the prescription and be aware of any import restrictions in the destination country.
Calcium supplements are not contraindicated and are often recommended to support bone health during aromatase inhibitor therapy.
Femara reduces estrogen production by inhibiting aromatase, while tamoxifen blocks estrogen receptors. Both are used in breast cancer but have distinct mechanisms, side-effect profiles, and indications.
Femara is prescribed for postmenopausal women; it does not induce menstrual cycles. In off-label fertility use, it may affect ovulation timing, but this requires specialist supervision.
Return unused tablets to a pharmacy or follow local hazardous waste guidelines. Do not discard them in household trash or flush them down the toilet.
